Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Blood Pressure Reduction Ineffective in Acute Stroke Treatment

By HospiMedica International staff writers
Posted on 02 Dec 2013
The use of antihypertensive drugs to lower systolic blood pressure (SBP) as part of the acute treatment of ischemic stroke does not reduce early mortality or disability, according to a new study.

Researchers at Tulane University (New Orleans, LA, USA) and Soochow University (Suzhou, China) conducted a single-blind, randomized clinical trial involving 4,071 patients with nonthrombolyzed ischemic stroke within 48 hours of onset, together with elevated SBP. More...
The patients were randomly assigned to receive antihypertensive treatment, aimed at lowering SBP by 10%–25% within the first 24 hours after randomization (2,038 patients), or to discontinue all antihypertensive medications during hospitalization (2,033 controls). The primary outcome was a combination of death and major disability at 14 days or hospital discharge.

The results showed that at 14 days after randomization, there were 683 events among patients who received early aggressive antihypertensive therapy, versus 681 events in the control group. At three months, there were 500 additional events in the treatment arm versus 502 among controls. The lack of benefit occurred despite the fact that antihypertensive therapy achieved a rapid and significant reduction in SBP, down from 166.7 mmHg to 144.7 mmHg (12.7% reduction) within 24 hours, versus a 7.2% reduction in the control group. The study was published online on November 17, 2013, in the Journal of the American Medical Association (JAMA).

“Among patients with acute ischemic stroke, blood pressure reduction with antihypertensive medications, compared with the absence of hypertensive medication, did not reduce the likelihood of death and major disability at 14 days or hospital discharge,” concluded lead author Jiang He, MD, PhD, and colleagues.

Typically, more attention is given to SBP as a major risk factor for cardiovascular disease (CVD) in people 50 years old and over. In most people, SBP rises steadily with age due to increasing stiffness of large arteries, long-term build-up of plaque, and increased incidence of CVD.

Related Links:

Tulane University
Soochow University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.